NCT04345913 2026-03-18
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
National Cancer Institute (NCI)
University of Washington
Zhejiang Cancer Hospital
BioNTech SE